Blumenkranz Mark S.
CIK: 0001614869
Associated companies
Transaction History
| KALA | ▲ Buy | Grant | 1,400 | $0 | 6/11/2024 | View on chart |
| KALA | ▲ Buy | Grant | 3,784 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 1,100 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 1,640 | — | 5/31/2023 | View on chart |
| KALA | ▲ Buy | Grant | 2,013 | — | 3/10/2023 | View on chart |
| KALA | ▲ Buy | Grant | 65,634 | — | 3/10/2023 | View on chart |
| KALA | ▲ Buy | Grant | 497 | — | 3/10/2023 | View on chart |
| KALA | ▼ Sell | Other | 3 | — | 2/15/2023 | View on chart |
| KALA | ▼ Sell | Other | 68 | — | 2/15/2023 | View on chart |
| KALA | ▼ Sell | Other | 2 | — | 2/15/2023 | View on chart |
| KALA | ▲ Buy | Grant | 157,765 | — | 11/15/2021 | View on chart |
| KALA | ▲ Buy | Grant | 5,144,390 | — | 11/15/2021 | View on chart |
| KALA | ▲ Buy | Grant | 38,965 | — | 11/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.